METTL3 and breast cancer: Li et al (145) found that the m6A modification of METTL3 increased the level of MALAT1 protein, recruited E2F1 and activated the transcription of downstream anterior gradient 2, protein disulphide isomerase family member, contributing to doxorubicin resistance in BC.